The Developmental Projects Program will sponsor efforts to complement or enhance the variety and depth of sarcoma translational research and will seek to ensure continual renewal of high-quality scientific endeavors in the SARC Sarcoma SPORE. The Program will support short-range studies to establish the results needed to facilitate well-validated, hypothesis-driven translational projects. Although the Developmental Projects Program will fund established investigators, an important goal is to identify and stimulate interest in sarcoma research among groups whose current focus may be different but sufficienfiy related. The Program may also fund projects that contribute to the infrastructure needed to achieve translational goals, such as creafion of suitable fissue resources or development of a new assay to monitor tumor behavior. The Developmental Projects Program is led by Francis Hornicek, an orthopaedic oncologist and co-Director, MGH/DF/HCC Sarcoma Group, whose laboratory evaluates mechanisms of sarcoma drug resistance, and Paul Meltzer, Chief of the Genefics Branch at the Center for Cancer Research, NCI, a pediatric oncologist who examines genomic mechanisms in sarcoma pathogenesis. In addifion, a highly qualified committee of experienced clinician-scientists will participate actively in the selecfion and ongoing review of pilot projects. The committee includes members with expertise in key aspects of sarcoma science and therapeufics, including biology and genetics (Drs. Pollock, Look and J. Fletcher);animal models (Drs. Khanna and Look), developmental therapeufics (Drs. Demetri and Pienta), clinical trials (Drs. Pollock, Pienta, and Demetri), correlafive science (Drs. Khanna and J. Fletcher), sarcoma pathology and molecular diagnosfics(Drs. C. Fletcher, Hamilton, and J. Fletcher), sarcoma genomics (Dr. Meltzer and J. Fletcher), sarcoma drug resistance (Dr. Homicek), and comparative oncology (Dr. Khanna). This committee includes representafives from Brigham and Women's Hospital, Dana-Farber Cancer Insfitute, Children's Hospital - Boston, Massachusetts General Hospital Cancer Center, MD Anderson Cancer Center, University of Michigan, and the National Cancer Insfitute. Nurturing innovations in translafional research is a labor-intensive activity, which must occur in cross-disciplinary fashion, and therefore the Developmental Projects Committee includes representation of pediatric oncology, medical oncology, surgical oncology, orthopaedic oncology, veterinary medicine (comparative oncology), pathology, and basic science. The Developmental Projects Program will provide the depth and flexibility required to maintain innovation in SARC Sarcoma SPORE.

Public Health Relevance

The Developmental Research Program will maximize the SPORE impact by enabling novel translafional sarcoma projects to develop and mature. These developmental projects will add new concepts to the SPORE, and will ensure that the SPORE translatlonal/clinical progress remains vigorous and with a varied portfolio of experimental work to draw upon, for main projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA168512-03
Application #
8725497
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
3
Fiscal Year
2014
Total Cost
$153,157
Indirect Cost
$9,602
Name
Sarc
Department
Type
DUNS #
186146911
City
Ann Arbor
State
MI
Country
United States
Zip Code
48106
Feng, Yong; Sassi, Slim; Shen, Jacson K et al. (2015) Targeting CDK11 in osteosarcoma cells using the CRISPR-Cas9 system. J Orthop Res 33:199-207
Monument, Michael J; Johnson, Kirsten M; McIlvaine, Elizabeth et al. (2014) Clinical and biochemical function of polymorphic NR0B1 GGAA-microsatellites in Ewing sarcoma: a report from the Children's Oncology Group. PLoS One 9:e104378
Choy, Edwin; Butrynski, James E; Harmon, David C et al. (2014) Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer 14:813
Kernstine, Kemp H; Moon, James; Kraut, Michael J et al. (2014) Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220. Ann Thorac Surg 98:402-10
Sankar, Savita; Theisen, Emily R; Bearss, Jared et al. (2014) Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth. Clin Cancer Res 20:4584-97
Zhang, Pingyu; Garnett, Jeannine; Creighton, Chad J et al. (2014) EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesis. J Pathol 232:308-18
Sioletic, Stefano; Czaplinski, Jeffrey; Hu, Lan et al. (2014) c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas. J Pathol 234:190-202
Chen, Eleanor Y; DeRan, Michael T; Ignatius, Myron S et al. (2014) Glycogen synthase kinase 3 inhibitors induce the canonical WNT/?-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma. Proc Natl Acad Sci U S A 111:5349-54
Krook, Melanie A; Nicholls, Lauren A; Scannell, Christopher A et al. (2014) Stress-induced CXCR4 promotes migration and invasion of ewing sarcoma. Mol Cancer Res 12:953-64
Jia, Bin; Choy, Edwin; Cote, Gregory et al. (2014) Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells. Cancer Lett 342:104-12

Showing the most recent 10 out of 13 publications